Online citations, reference lists, and bibliographies.
← Back to Search

Transmucosal Macromolecular Drug Delivery.

C. Prego, M. García, D. Torres, M. Alonso
Published 2005 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Mucosal surfaces are the most common and convenient routes for delivering drugs to the body. However, macromolecular drugs such as peptides and proteins are unable to overcome the mucosal barriers and/or are degraded before reaching the blood stream. Among the approaches explored so far in order to optimize the transport of these macromolecules across mucosal barriers, the use of nanoparticulate carriers represents a challenging but promising strategy. The present paper aims to compare the characteristics and potential of nanostructures based on the mucoadhesive polysaccharide chitosan (CS). These are CS nanoparticles, CS-coated oil nanodroplets (nanocapsules) and CS-coated lipid nanoparticles. The characteristics and behavior of CS nanoparticles and CS-coated lipid nanoparticles already reported [A. Vila, A. Sanchez, M. Tobio, P. Calvo, M.J. Alonso, Design of biodegradable particles for protein delivery, J. Control. Rel. 78 (2002) 15-24; R. Fernandez-Urrusuno, P. Calvo, C. Remunan-Lopez, J.L. Vila-Jato, M.J. Alonso, Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm. Res. 16 (1999) 1576-1581; M. Garcia-Fuentes, D. Torres, M.J. Alonso, New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin (submitted for publication).] are compared with those of CS nanocapsules originally reported here. The three types of systems have a size in the nanometer range and a positive zeta potential that was attributed to the presence of CS on their surface. They showed an important capacity for the association of peptides such as insulin, salmon calcitonin and proteins, such as tetanus toxoid. Their mechanism of interaction with epithelia was investigated using the Caco-2 model cell line. The results showed that CS-coated systems caused a concentration-dependent reduction in the transepithelial resistance of the cell monolayer. Moreover, within the range of concentrations investigated, these systems were internalized in the monolayer in a concentration-dependent manner. This uptake was slightly enhanced by the presence of the CS coating but, as compared with previously published results [M. Garcia-Fuentes, C. Prego, D. Torres, M.J. Alonso, Triglyceride-chitosan nanostructures for oral calcitonin delivery: evaluation in the Caco-2 cell model and in vivo (submitted for publication)], highly dependent on the nature of the lipid core. Nevertheless, these differences in the uptake of the CS-coated systems (solid lipid core or oily core) by the Caco-2 cells did not have a consequence in the in vivo behaviour. Indeed, both CS-coated systems (nanocapsules and CS-coated nanoparticles) showed an important capacity to enhance the intestinal absorption of the model peptide, salmon calcitonin, as shown by the important and long-lasting decrease in the calcemia levels observed in rats.
This paper references
10.1021/BK-2004-0879.CH020
Biodegradable Nanoparticles as New Transmucosal Drug Carriers
M. J. Alonso (2004)
10.1081/PDT-100100522
Mucoadhesive DL-Lactide/Glycolide Copolymer Nanospheres Coated with Chitosan to Improve Oral Delivery of Elcatonin
Y. Kawashima (2000)
10.1016/S0927-7765(99)00157-5
The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration.
Tobío (2000)
10.1016/S0169-409X(00)00123-X
Polysaccharide colloidal particles as delivery systems for macromolecules.
K. Janes (2001)
10.1016/S0928-0987(99)00032-9
Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
N. G. Schipper (1999)
Novel approaches to nasal delivery of peptides and proteins
G. Tirucherai (2002)
10.1016/0378-5173(92)90353-4
In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers
C. Lehr (1992)
Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration
R. Fernández-Urrusuno (1999)
10.2337/diab.37.2.246
New Approach for Oral Administration of Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier
C. Damgé (1988)
10.1016/S0168-3659(02)00411-X
Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats.
H. Takeuchi (2003)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1016/J.BIOPHA.2004.01.007
Nanomedicines for overcoming biological barriers.
M. Alonso (2004)
10.1023/A:1018908705446
Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles
R. Fernández-Urrusuno (2004)
10.1016/S0378-5173(97)00083-5
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers
P. Calvo (1997)
10.1016/S0378-5173(99)00030-7
Effect of chitosan on epithelial permeability and structure.
V. Dodane (1999)
10.1016/S0169-409X(98)00037-4
The effect of physical barriers and properties on the oral absorption of particulates.
Norris (1998)
10.1089/0894268041457183
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
10.1007/S003960050050
Development of positively charged colloidal drug carriers: Chitosan-coated polyester nanocapsules and submicron-emulsions
P. Calvo (1997)
10.1002/PAT.280
PLA‐PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA
A. Vila (2002)
10.1023/B:PHAM.0000012150.60180.e3
Effect of Chitosan on Epithelial Cell Tight Junctions
J. Smith (2004)
10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers
P. Calvo (1997)
10.1023/A:1012029517394
The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual
A. Florence (2004)
10.1016/J.METABOL.2003.07.021
Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial.
S. Clement (2004)
10.1016/S0278-6915(00)00136-8
Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats.
J. DeSesso (2001)
10.1023/A:1011922819926
Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration
M. Tobío (2004)
10.1023/A:1012126301290
The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
M. P. Desai (2004)
10.1016/S0378-5173(02)00486-6
Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo.
Yan Pan (2002)
10.1023/B:PHAM.0000016249.52831.a5
Uptake and Cytotoxicity of Chitosan Molecules and Nanoparticles: Effects of Molecular Weight and Degree of Deacetylation
M. Huang (2004)
10.1016/S0928-0987(03)00178-7
The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.
A. M. de Campos (2003)
10.1016/S0927-7765(02)00053-X
Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules
M. Garcia-Fuentes (2003)
10.1002/JPS.10129
Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
G. Zara (2002)
10.1016/S0140-6736(00)03638-2
Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study
J. Skyler (2001)
10.1016/S1773-2247(06)50061-9
Chitosan nanocapsules: a new carrier for nasal peptide delivery
C. Prego (2006)
10.1002/PAT.98
Palladium complexes of side‐chain liquid crystal polymers with T‐shaped two‐dimensional mesogenic units
S. Zhang (2002)
10.1002/PSC.366
Peptides as Drugs: Is There a Market?
A. Loffet (2002)
10.1023/A:1018967116988
Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2)
P. Artursson (2004)
10.1016/J.EJPS.2005.02.008
A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.
M. Garcia-Fuentes (2005)
10.1023/A:1019854327540
Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport
I. Behrens (2004)
10.1023/A:1016444808000
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells
N. G. Schipper (2004)



This paper is referenced by
TOXICITY OF CHITOSAN BASED PRODUCTS
Adina MATICA (2017)
10.1016/j.ejpb.2007.12.012
Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutylcyanoacrylate) core-shell nanoparticles.
I. Bravo-Osuna (2008)
10.2165/00063030-200822040-00002
Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation
Camile B. Woitiski (2012)
10.4103/0250-474X.95608
Noninvasive Routes of Proteins and Peptides Drug Delivery
Jitendra (2011)
10.3109/10837450.2011.591804
A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing
J. Fangueiro (2013)
10.22092/ARI.2008.103739
PREPARATION AND IN-VITRO EVALUATION OF SODIUM ALGINATE MICROSPHERES CONTAINING DIPHTHERIA TOXOID AS NEW VACCINE DELIVERY
A. Mokaram (2008)
10.1016/j.ejpb.2009.02.013
The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione.
A. Lopedota (2009)
10.4155/TDE.12.16
Hydrogels in mucosal delivery.
Hamde Nazar (2012)
EXPLORING SOLID LIPID NANOPARTICLES FOR INTRANASAL ADMINISTRATION OF STREPTOMYCIN
Indu Pal Kaur (2011)
10.1016/J.IJPHARM.2005.11.049
Lipidic implants for controlled release of bioactive insulin: effects on cartilage engineered in vitro.
B. Appel (2006)
10.1201/B11035-4
Nanocapsules as Carriers for the Transport and Targeted Delivery of Bioactive Molecules
P. Hervella (2011)
10.1021/la404558g
The amine content of PEGylated chitosan Bombyx mori nanoparticles acts as a trigger for protein delivery.
Daniela Vásquez (2014)
Vectorización del extracto de Physalis peruviana L. en nuevos sistemas de liberación de uso farmacéutico
Baena Aristizábal (2019)
Dual strategies to correct abnormal ion transports in cystic fibrosis using construct therapy
A. K. Kolonko (2019)
10.1016/j.colsurfb.2009.12.020
Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin.
Jing Zhang (2010)
10.1007/s00204-012-0827-1
Cytotoxicity of hydroxyapatite nanoparticles is shape and cell dependent
X. Zhao (2012)
10.1002/MASY.201300186
Preparation of Unsaturated Fatty Acids/Chitosan Microcapsules: Influence of Solvent
V. M. Esquerdo (2014)
10.1007/978-1-4939-1417-3_11
Gels as Vaccine Delivery Systems
Sarah Gordon (2015)
10.1007/s10571-019-00727-y
Glioprotective Effect of Chitosan-Coated Rosmarinic Acid Nanoemulsions Against Lipopolysaccharide-Induced Inflammation and Oxidative Stress in Rat Astrocyte Primary Cultures
F. N. S. Fachel (2019)
10.6000/1929-5030.2015.04.02.2
Polymeric Versus Lipid Nanoparticles: Comparative Study of Nanoparticulate Systems as Indomethacin Carriers
Ana Amélia Carvalho (2015)
10.2147/IJN.S119033
The nasal delivery of nanoencapsulated statins – an approach for brain delivery
A. Clementino (2016)
10.1016/j.biomaterials.2011.03.005
The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Ran Mo (2011)
10.1016/J.JCONREL.2005.12.015
Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree.
C. Prego (2006)
10.1016/J.JCONREL.2006.08.013
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
A. des Rieux (2006)
10.1016/S1773-2247(08)50075-X
Mucoadhesive drug carriers and polymers for effective drug delivery
Abdallah Makhlof (2008)
10.1007/s13346-012-0105-z
Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide
S. S. Chavan (2012)
10.4155/tde-2016-0031
What is the future of noninvasive routes for protein- and peptide-based drugs?
Sameer Sachdeva (2016)
SOLID LIPID NANOPARTICLES TECHNOLOGY AS A NOVEL PLATFORM FOR DELIVERY OF DRUGS
A. Bhattacharjee (2013)
Developing oral formulations for protein and peptide drugs
A. Parry (2013)
10.1016/J.IJPHARM.2006.02.031
Preparation and characterization of mucoadhesive polymer-coated nanoparticles.
Fuying Cui (2006)
10.1007/978-1-4614-9164-4_6
The Potential of Nanoemulsions in Biomedicine
M. Mazza (2013)
10.1016/j.ijpharm.2009.10.018
Polymer-based nanocapsules for drug delivery.
C. E. Mora-Huertas (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar